

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CANbridge Pharmaceuticals Inc.**

**北海康成製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1228)**

**CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board (“**Board**”) of directors (the “**Directors**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that the principal place of business of the Company in Hong Kong changes to 40th Floor, Dah Sing Financial Centre, No.248 Queen’s Road East, Wanchai, Hong Kong with effect from July 11, 2025. The website of the Company remain unchanged.

By Order of the Board  
**CANbridge Pharmaceuticals Inc.**  
**Dr. James Qun Xue**  
*Chairman*

Hong Kong, July 11, 2025

*As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Wei Zhao as non-executive Director, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.*